# A Retrospective Review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P) With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

> **NCT00301301** · — · COMPLETED · sponsor: **Royal Marsden NHS Foundation Trust** · enrollment: 39 (—)

## Conditions studied

- Non-Hodgkins Lymphoma

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Cisplatinum
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00301301
- **Lead sponsor:** Royal Marsden NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 39 (—)
- **Last updated:** 2010-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00301301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00301301, "A Retrospective Review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P) With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00301301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*